By 2030, the PharmEco Group plans to build a pharmaceutical production facility in the Chernogolovka urban district of the Moscow Region to manufacture cancer drugs. Investments in the project are estimated at 9.1 billion rubles. A trilateral agreement on its creation was signed on the sidelines of the St. Petersburg International Economic Forum (SPIEF 2025) between the Ministry of Investment, Industry and Science of the Moscow Region, PharmEco Group, and Sber.
Production is scheduled to begin in 2029. Once the facility reaches its design capacity, the company is expected to have full cycle production of 18 drugs there. According to the signed agreement, Sber will provide partial financing for the project.
The pharmaceutical company has already leased a 30,000-square-meter plot of land. The production area will span more than 10,000 square meters. 150 jobs will be created at the enterprise.
PharmEco Group was founded in 2001. The company is engaged in the production and distribution of medicines. The group’s production sites are located in Moscow, Podolsk (Moscow region), Ryazan, and Novosibirsk. In 2022, it became known that the group would localize Evrysdi (risdiplam), an oral therapy for the treatment of spinal muscular atrophy (SMA), originally developed by the Swiss company Roche, at its Dobrolek production site in Moscow.
